Oceania Healthcare (OCA) H1 2025 earnings summary

Executive summary

• Underlying EBITDA increased 2.7% year-over-year to $38.6m for the six months ending 30 September 2024, reflecting improved sales, portfolio rebalancing, and strong operational cash flow.

• CEO Suzanne Dvorak appointed in July 2024, with a focus on sales execution, debt reduction, and operational efficiency.

• Portfolio rebalancing continues, with divestments and new developments shifting towards premium care and retirement units.

• Dividend remains paused due to gearing, with resumption expected after sufficient stock sell-down and leverage reduction.

• Sustainability initiatives advanced, including SBTi-validated GHG reduction targets, Homestar/Greenstar standards, and recognition as a Deloitte Top 200 Awards finalist.

Financial highlights

• Operating revenue increased 1% to $132.6m in HY25 compared to HY24.

• Underlying NPAT was $24.0m, down 12.5% year-over-year, while realised capital gains grew 34.9% to $38.2m.

• Operating cash flow rose 23.1% to $70.4m, driven by a 59.8% increase in new ORA receipts.

• Total assets reached $2.8bn, up $38.9m from FY24; net tangible assets per share increased to $1.43.

• Reported total comprehensive income was $11.8m, down from $61.7m in 1HY24, impacted by property fair value movements and impairments.

Outlook and guidance

• Focus remains on accelerating sales, especially at The Helier, reducing unsold stock, and lowering gearing.

• Transitioning development pipeline to villa products for improved capital recycling and flexibility.

• Portfolio mix targeted at 50% care/50% ILU, with further divestments and new developments planned.

• $5m right-sizing/cost-out program underway, with benefits expected in FY26.

• Board expects to resume dividends once new stock and gearing are sufficiently reduced.